Patients and Methods
The study summarizes our experience in children with primary idiopathic nephrotic syndrome in whom the renal biopsy revealed MesPGN and significant IgM deposits. Patients with MesPGN secondary to a known infectious or systemic disease were excluded. Patients were seen at Jordan University Hospital, Department of Pediatrics, during the period between July 1988 to March 2002. Our analysis includes the patient's history, family history, physical findings, laboratory findings, renal biopsy, and the treatment offered.
All patients underwent renal biopsy. Renal biopsies were performed under ultrasound guidance using a 16-gauge biopsy needle. Biopsy samples were evaluated by light microscopy (using hematoxylin and eosin, periodic acid-Schiff, Masson-Trichrome, and Congo red stains). Immunoflourescent (IF) microscopy was performed on all biopsies, and included staining for IgM, IgG, IgA, C3, C4, and fibrinogen. Biopsies were read first by the pathologist, and then reviewed by the author with the same pathologist. The final diagnosis was made on the basis of histologic and clinical data. The diagnosis was assigned using standard histological classifications. IgM nephropathy was defined as diffusely increased mesangial hypercellularity, often with diffusely increased mesangial matrix, absence of segmental sclerosis on light microscopy, and predominant segmental or diffuse deposition of IgM in the mesangium on IF microscopy. Patients with biopsies that were inadequate for light microscopy or IF, or both, were excluded. A repeat kidney biopsy was done in five patients who had steroid dependent/frequent relapsing NS (SDFR-NS) (Table 1: patients 2, 4, 7, 10, and 16), and in 9 patients with steroid resistant NS (SR-NS) ( Table 2:  patients 1, 5, 9, 13, 14, 16, 17, and Table 3 : patients 2 and 6).
All patients with a diagnosis of NS received daily prednisolone (2mg/kg, maximum, 80 mg/m 2 /day) until they achieved remission, followed by tapering over two months in steroid-responsive patients. Patients unresponsive to prednisolone therapy for four weeks were considered resistant, and were kept on the same amount of prednisolone (2 mg/kg) as a single dose on alternate days for an additional four weeks, and subsequently tapered if they showed no response. Patients who relapsed during steroid tapering, and those who had frequent relapses (more than four relapses/ year) were treated with the alternate-day prednisolone regimen for several months at the lowest dose that maintained remission.
Cyclosporine A (CsA)(Neoral) therapy was offered to 10 patients who had frequent relapsing steroid-dependent NS, and to 17 steroid-resistant NS patients. CsA was started in eligible children at a dose of 5 mg/kg body weight per day, given in two divided doses after the patients had attained remission with prednisolone, or once the diagnosis of steroid resistance was made. The dose of CsA was adjusted to maintain whole blood trough levels at 60-180 ng/mL (HPLC).
In patients who continued to have proteinuria after one month of CsA treatment, 24-hour urine was collected monthly to assess the degree of proteinuria. Complete remission was defined as negative or trace proteinuria by dipstick for at least 7 consecutive days. the serum albumin level normalized and no edema. Partial remission was defined as significant and sustained improvement in serum albumin, edema, and proteinuria, but without complete normalization, with serial 24-hour urine collections quantitatively showing at least a 50% drop in the degree of proteinuria. In these patients, 24-hour urine protein was always •1 g. Patients were considered to be CsA-resistant if they failed to respond after 16 weeks of therapy, and CsA was subsequently discontinued. In patients who had either a complete or partial remission, CsA was continued for a minimum of 9 months. Patients who relapsed soon after discontinuing CsA, and those with subsequent frequent relapses were offered treatment again with CsA. Clinical evaluation and monitoring of CsA toxicity was repeated every four weeks. All patients had normal kidney function at the onset of CsA treatment. During the follow-up period, serum creatinine, urea, uric acid, liver enzymes, proteins, and creatinine clearance were measured regularly.
Results
Of the 41 patients, 25 (61%) were males, and 16 (39%) were females. The mean age at onset of presentation was 5.7 years (range 0.75-13 years), and the mean follow-up period was 4.2 years (range 1-13 years). Demographic data on all patients is included in Tables 1,2 , and 3.
All biopsies were adequate for histologic evaluation, with an average number of glomeruli of 22 (range 16-32). All biopsies had glomeruli for IF staining. The average follow-up period from the diagnosis of nephrotic syndrome to the performance of renal biopsy was 17 months (range 14-28 months). Light microscopy in all biopsies revealed the presence of significant mesangial expansion and hypercellularity. Thickening of the glomerular capillary wall and interstitial/tubular changes were absent in all samples. None of the biopsies had evidence of focal segmental glomerulosclerosis. Significant (≥2+) predominant segmental or diffuse mesangial deposits of C3 IgG were present in some cases. These glomerular IF deposits of C3 were seen in 11 biopsies (Table 1 : patients 1, 6, 13, 17), ( (Table 3 : patients 2, 5). Glomerular deposits of C3 and IgG did not seem to influence the outcome of patients, but no conclusions could be drawn with certainty due to the small number of these deposits in the different groups of patients. None of the repeat biopsies revealed evidence of focal segmental glomerulosclerosis. The average time of repeat biopsy among patients who had a biopsy repeated was 2.5 years (range 1.5-4 years). None of the patients included in this series had steroid sensitive nephrotic syndrome with infrequent relapses since we did not biopsy such patients. Table 1 summarizes the clinical characteristics of the 17 children with SDFR-NS. Tables 2 and 3 show the clinical characteristics of the 24 SR-NS patients. Microscopic hematuria was common (59%). Hematuria was more common in SR-NS than in SDFR-NS patients (79% and 29%, respectively), and this difference was statistically significant (P<0.005). Twenty patients (49%) had hypertension. More patients with SR-NS (71 %) had hypertension than SDFR-NS patients (18%), and this difference was statistically significant (P<0.001).
Therapy with prednisolone (Table 1) revealed that 17 patients (12 boys, 5 girls) had SDFR-NS. Twenty-four children (13 boys, 11 girls) had SR-NS (Tables 2, 3 ). Ten patients with SDFR-NS received CsA (Table 1) , and all patients with SDFR-NS that received CsA responded, having either no relapses during therapy (6 patients) or infrequent relapses (4 patients). Following cessation of CsA therapy, 3 patients developed frequent relapsing courses, and the rest (7 patients) had infrequent relapses. CsA was offered to these patients for periods varying from 12 to 32 months (mean 18.7 months). Seventeen patients with SR-NS received CsA (Table 2 ). Eight patients responded to CsA, and two other patients (1, 9) had a partial response with a significant (>50 %) decline in the degree of proteinuria whilst on CsA therapy. Seven patients showed no response to CsA, two of whom developed gradual loss of renal function and eventually died with end stage renal failure.
Seven patients with SR-NS did not receive CsA (Table 3) . Four of these continued to have significant proteinuria but maintained a normal glomerular filtration rate (GFR). Two other patients died with end stage renal failure, and 1 other patient had spontaneous resolution of proteinuria. There were no significant changes in renal function or blood pressure during CsA therapy. Repeat renal biopsy was not performed in any patient to assess the effect of CsA therapy. Cyclosphosphamide 2.5 mg/kg body weight/day was offered to one SR-NS patient (patient 1, Table 3 ) for 13 weeks, but was not beneficial.
Discussion
Among patients with NS, MesPGN is a relatively uncommon glomerular lesion usually defined by its light microscopic features. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] It is found as an uncomplicated lesion in less than 10 percent of biopsies in patients with idiopathic NS, although some series have demonstrated an overall prevalence of proliferative GN (other than mesangiocapillary glomerulonephritis) as high as 20 percent. We have noted a relatively high incidence (15%) of MesPGN among Jordanian children with NS. 24 Interest in IgM labeling dates from two reports in the late 1970s. 18, 19 After these reports, a series of studies appeared that were often conflicting. Some investigators 20, 21 considered NS with mesangial IgM deposits to be a unique entity, often referred to as "IgM nephropathy." This condition was thought to be associated with steroid resistance and was said to progress frequently to FSGS and renal insufficiency. On the other hand, other workers 22, 23 considered IgM mesangial labeling to be a non-specific feature of no prognostic significance.
Childhood NS generally has a benign long-term prognosis. However, children with SD-NS and SR-NS incur substantial morbidity with respect to infection, hypertension, thrombosis, growth failure, and psychosocial disruption. Although systemic steroids are adequate to treat the vast majority of children with NS, a significant proportion of patients become seriously debilitated, either by the disease itself or by its treatment. Other immunosuppressive agents are effective in controlling morbidity for many of these patients, but there remain some children who are not responsive to this therapy. Cyclosporine was first used in such patients in 1985. Although these patients may greatly benefit from CsA therapy, it remains unclear in which clinical and histological subgroups of patients with NS that the benefits outweigh the long-term risk of CsA nephrotoxicity. The variable response of patients with NS to CsA, the potential for CsA-dependence, and the uncertain risk for chronic nephrotoxicity pose a dilemma for the pediatric nephrologist. Our early experience with MesPGN found that there was a favorable response to CsA therapy, both in SD-NS and SRNS patients. 25 Little data are available in the literature on the response to CsA among patients with IgM nephropathy, a histologic classification that may have a prognosis intermediate between minimal change NS and focal segmental glomerulosclerosis. 21, 26, 27 Most of the data is from patients with IgM nephropathy with SD-NS, which responds like MCNS, having a response to CsA between 83% to 100%. The few SR-NS patients with IgM nephropathy reported in the literature have not shown response to CsA therapy. [28] [29] [30] [31] The presence of a relatively large number of children with IgM nephropathy in Jordan makes this a unique group of patients not commonly reported in the literature, and has allowed us to examine the responsiveness of this lesion to steroids and CsA. Although authors have differed in their opinions on the clinical relevance of significant IgM deposition, this disorder has been reported to have a high rate of steroid non-responsiveness (30% to 50%) compared to MCNS. 21, 26, 27, 32, 33 Our ability to induce and/or maintain complete remission in 70% of patients with IgM nephropathy suggests that prednisolone combined with CsA can be highly effective for this histologic group of NS patients.
In summary, this analysis of the long-term risks and benefits of CsA for a group of children with mesangial IgM nephropathy has identified two important findings: (1) combined CsA and alternate-day steroids can be highly effective in inducing complete remission in patients with SR-NS, and (2) long-term use of CsA in moderate doses with closely monitored levels can result in a relatively low incidence of nephrotoxicity. Furthermore, children with steroid resistant and/or cyclosporine resistant MesPGN ("IgM nephropathy ") can have progressive loss of renal function and subsequent end-stage renal failure.
